Drugs / Sodium Pyruvate
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00308243 | Mar 2006 → Mar 2007 | cystic fibrosis | Emphycorp | Completed | No outcome recorded |
| Phase 1 | NCT00332215 | Feb 2006 → ? | cystic fibrosis | University of Minnesota | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00262652 | Jan → Sep 2006 | — | Emphycorp | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00262613 | Sep 2004 → May 2006 | chronic obstructive pulmonary disease | Emphycorp | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04871815 | Apr 2021 → Mar 2022 | long COVID-19 | Cellular Sciences, inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04824365 | Apr 2021 → Aug 2022 | COVID-19 | Cellular Sciences, inc. | Completed | Mixed |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT06037408 | Aug 2023 → May 2024 | idiopathic pulmonary fibrosis | Cellular Sciences, inc. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Pyruvate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00308243 ↗ |
| Known as | N115 | “The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2 (N115).” NCT06037408 ↗1“In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days.” NCT04824365 ↗ |
| Route | Inhaled | “inhaled sodium pyruvate” NCT00262613 ↗ |